Drug Repositioning for Alzheimer’s Disease Based on Systematic ‘omics’ Data Mining

• DOI: 10.1371/journal.pone.0168812
• Publication Date: 2017-01-09T16:31:46Z
• Authors: Ming Zhang; Gerold Schmitt-Ulms; Christine Sato; Zhengrui Xi; Yalun Zhang; Ye Zhou; Peter St George-H...; Ekaterina Rogaeva
• Keywords: Drug repositioning; DrugBank; Omics; Repurposing; Drug Development

Traditional drug development for Alzheimer's disease (AD) is costly, time consuming and burdened by a very low success rate. An alternative strategy repositioning, redirecting existing drugs another disease. The large amount of biological data accumulated to date warrants comprehensive investigation better understand AD pathogenesis facilitate the process anti-AD repositioning. Hence, we generated list protein targets analyzing most recent publically available 'omics' data, including genomics, epigenomics, proteomics metabolomics data. information related was obtained from OMIM PubMed databases. Drug-target extracted DrugBank Therapeutic Target Database. We 524 AD-related proteins, 18 which are 75 drugs-novel candidates repurposing as treatments. developed ranking algorithm prioritize targets, revealed CD33 MIF strongest with seven drugs. also found 7 inhibiting known target (acetylcholinesterase) that may be repurposed treating cognitive symptoms AD. CAD 8 proteins implicated two approaches (ABCA7, APOE, BIN1, PICALM, CELF1, INPP5D, SPON1, SOD3) might promising development. Our systematic mining suggested novel indications, modulating immune system or reducing neuroinflammation particularly intervention. Furthermore, could useful not only potential but considered biomarker